The biopharmaceutical industry is currently facing pressure from expiring patents, which are expected to result in a $100 billion headwind for the industry over the next five years. However, that headwind should be more than matched by growth of newly approved drugs.
According to US financial services company Morningstar’s recently published “Biopharmaceuticals Industry Landscape,” revenue at the top 18 biopharma companies under Morningstar’s coverage is expected to grow at 5.2% annually through 2028.
Key highlights from the report include:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze